Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + cisplatin
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab + cisplatin is a combination therapy used primarily in the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab is a monoclonal antibody that selectively binds to the extracellular domain of the epidermal growth factor receptor (EGFR), inhibiting its activation and downstream signaling, which leads to reduced tumor cell proliferation and increased apoptosis. Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. The combination has been shown to improve overall survival and disease-free survival compared to chemotherapy alone, particularly as part of regimens like the EXTREME protocol. This combination can also help overcome resistance mechanisms such as epithelial-mesenchymal transition (EMT) seen with cisplatin monotherapy[1][2][6].
- Other names
- CDDPcis-diamminedichloroplatinum(II)
02
Targets
Beyond the preview
Go deeper on cetuximab + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + cisplatin.